Patents Represented by Attorney, Agent or Law Firm J. Timothy Meigs
  • Patent number: 6649375
    Abstract: An adenoviral vector including at least one DNA sequence encoding a clotting factor, such as, for example, Factor VIII, or Factor IX. Such vectors may be administered to a host in an amount effective to treat hemophilia in the host. The vectors infect hepatocytes very efficiently, whereby the hepatocytes express the DNA sequence encoding the clotting factor.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: November 18, 2003
    Assignee: Genetic Theraphy, Inc.
    Inventors: Sheila Connelly, Michael Kaleko, Theodore Smith
  • Patent number: 6638762
    Abstract: The invention generally relates to cell-specific expression vectors. It particularly relates to targeted gene therapy using recombinant expression vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional expression vectors and methods for using them. Such vectors are able to selectively replicate in a target cell or tissue to provide a therapeutic benefit in a tissue from the presence of the vector per se or from one or more heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: October 28, 2003
    Assignee: Genetic Therapy, Inc.
    Inventors: Yung-Nien Chang, Paul L. Hallenbeck, Carl M. Hay, David A. Stewart
  • Patent number: 6632981
    Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5′ region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: October 14, 2003
    Assignee: Novartis Finance Corporation
    Inventors: Frederick Meins, Jr., Hideaki Shinshi, Herman C. Wenzler, Jan Hofsteenge, John A. Ryals, Christoph Sperisen
  • Patent number: 6620595
    Abstract: The invention provides novel retroviral vectors that have enhanced transcription termination structures. The termination structures comprise one or several heterologous upstream transcription termination enhancer (UE) sequences, or one or more additional copies of endogenous UE sequences operably associated with the 3′ LTR polyadenylation signal. The retroviral vectors of the invention have various improved properties over conventional vectors, including stronger gene expression, enhanced vector titer and reduced interference with host cell gene expression resulting from read-through of vector initiated transcriptional events.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: September 16, 2003
    Assignee: University of Southern California
    Inventors: Paula Marie Cannon, Maria Barcova
  • Patent number: 6610534
    Abstract: A method of inducing blood vessel formation in an animal by administering to the animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof. The polynucleotide may be contained in an appropriate expression vector, such as a viral vector. The delivery of sphingosine kinase through administration of an expression vector which expresses sphingosine kinase provides for the formation of larger blood vessels containing a well defined structure that is supported by mural cells such as pericytes and smooth muscle cells.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: August 26, 2003
    Assignee: Novartis AG
    Inventors: Gene Liau, Steingrimur Stefansson, Joseph Su
  • Patent number: 6551587
    Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: April 22, 2003
    Assignee: Genetic Therapy, Inc.
    Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
  • Patent number: 6485907
    Abstract: Internal Transcribed Spacer (ITS) DNA sequences from the ribosomal RNA gene region are described for different strains of the wheat fungal pathogen, Rhizoctonia cerealis. Specific primers from within these sequences are identified as being useful for the identification of Rhizoctonia cerealis using PCR-based techniques.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: November 26, 2002
    Assignee: Syngenta Participations AG
    Inventors: James Joseph Beck, Charles Jason Barnett
  • Patent number: 6429360
    Abstract: The genes encoding a novel class of insecticidal proteins have been isolated and characterized from a strain of Bacillus thuringiensis. Both the nucleic and amino acid sequences for the proteins are disclosed. The nucleic acid molecules are utilized in the transformation of host microorganisms and production of transgenic plants which are resistant to insects. Also, the gene encoding for the insect's receptor of the insecticidal protein has been isolated and characterized. Novel processes and methods for controlling plants pests are provided.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: August 6, 2002
    Assignee: Syngenta Investment Corporation
    Inventors: Juan Jose Estruch, Gregory Wayne Warren, Nalini Manoj Desai, Michael Gene Koziel, Gordon James Nye
  • Patent number: 6392123
    Abstract: The present invention provides a method for hybrid seed production comprising producing a conditional female sterile plant comprising a female-preferential promoter operably linked to a coding sequence which encodes an enzyme which catalyzes the conversion of a protoxin to a toxin, interplanting the conditional female sterile plant with a male sterile plant, applying the protoxin to the conditional female sterile plant, and producing hybrid seed. Viable seed formation is prevented on the conditional female sterile plant as a result of the conversion of the protoxin to the toxin in the female reproductive structures, and pollen production is prevented on the male sterile plant, thus allowing interplanting of the two parents of the hybrid cross in order to provide more efficient pollen transfer. Also provided are expression cassettes useful in the invention, plants transformed with the expression cassette, and novel female-preferential promoters.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: May 21, 2002
    Assignee: Syngenta Participations AG
    Inventors: Stacy Marie Harper, Lyle Dean Crossland, Erica Pascal
  • Patent number: 6387637
    Abstract: The invention relates to genes isolated from Arabidopsis that code for proteins essential for seedling growth. The invention also includes the methods of using these proteins to discover new herbicides, based on the essentiality of the genes for normal growth and development. The invention can also be used in a screening assay to identify inhibitors that are potential herbicides. The invention is also applied to the development of herbicide tolerant plants, plant tissues, plant seeds, and plant cells.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: May 14, 2002
    Assignee: Syngenta Participations AG
    Inventors: Joshua Z. Levin, Gregory J. Budziszewski, Sharon L. Potter, Lynette M. Wegrich
  • Patent number: 6383787
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: May 7, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6362398
    Abstract: A novel promoter isolated from the 5′ flanking region upstream of the coding sequence of the Arabidopsis plastid clpP gene is described. Also described are a novel method for utilizing protein-coding regions of plastid genes to isolate intervening regulatory sequences and a novel method for improving plastid transformation efficiency using exogenous plastid promoters that differ in nucleotide sequence from native plastid promoters.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: March 26, 2002
    Assignee: Syngenta Participations AG
    Inventor: Peter Bernard Heifetz
  • Patent number: 6362394
    Abstract: The present invention is drawn to a method of controlling gene expression in plants. Specifically, the method comprises transforming a plant with a USP receptor expression cassette which encodes a USP receptor and at least one target expression cassette which encodes a target polypeptide. Contacting said transformed plant with juvenile hormone or one of its agonists activates expression of the target polypeptide in the presence of said USP receptor polypeptide. Optionally, additional “secondary” receptor expression cassettes may be used, wherein the secondary receptor expression cassette encodes a receptor polypeptide distinct from USP. The method is useful for controlling various traits of agronomic importance, such as plant fertility. Also disclosed is a method of identifying previously unknown ligands for USP. Substances to be tested are identified by placing them in contact with plant cells transformed with a USP receptor expression cassette and a target expression cassette.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: March 26, 2002
    Assignee: Syngenta Participations AG
    Inventors: Lyle Dean Crossland, Stephen Arthur Goff
  • Patent number: 6358680
    Abstract: Internal Transcribed Spacer (ITS) DNA sequences from the ribosomal RNA gene region are described for species and strains of wheat fungal pathogens, including Pyrenophora tritici-repentis and Pyrenophora teres. Specific primers from within these sequences are identified as being useful for the identification of the fungal isolates using PCR-based techniques.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: March 19, 2002
    Assignee: Syngenta Participations AG
    Inventor: James Joseph Beck
  • Patent number: 6358719
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 19, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355458
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355459
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355457
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6353159
    Abstract: An inbred maize line, designated NP2213, the plants and seeds of inbred maize line NP2213, methods for producing a maize plant produced by crossing the inbred line NP2213 with itself or with another maize plant, and hybrid maize seeds and plants produced by crossing the inbred line NP2213 with another maize line or plant.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: March 5, 2002
    Assignee: Syngenta Participations AG
    Inventor: Bruce Wayne Skillings
  • Patent number: 6346404
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: February 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach